Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E19.32 EPS (ttm)6.16 Insider Own0.10% Shs Outstand757.02M Perf Week0.04%
Market Cap90.11B Forward P/E13.61 EPS next Y8.74 Insider Trans32.11% Shs Float756.23M Perf Month1.00%
Income4.72B PEG2.63 EPS next Q2.07 Inst Own83.00% Short Float1.14% Perf Quarter2.28%
Sales18.96B P/S4.75 EPS this Y20.30% Inst Trans0.03% Short Ratio2.73 Perf Half Y0.96%
Book/sh30.04 P/B3.96 EPS next Y8.04% ROA7.80% Target Price132.18 Perf Year10.91%
Cash/sh26.16 P/C4.55 EPS next 5Y7.36% ROE21.70% 52W Range101.35 - 128.26 Perf YTD5.45%
Dividend2.44 P/FCF21.69 EPS past 5Y12.00% ROI10.50% 52W High-6.09% Beta0.53
Dividend %2.05% Quick Ratio3.10 Sales past 5Y4.50% Gross Margin80.50% 52W Low18.83% ATR2.09
Employees20000 Current Ratio3.50 Sales Q/Q6.70% Oper. Margin31.70% RSI (14)56.87 Volatility2.13% 1.77%
OptionableYes Debt/Eq1.41 EPS Q/Q-25.50% Profit Margin24.90% Rel Volume0.76 Prev Close119.03
ShortableYes LT Debt/Eq1.30 EarningsJul 29 AMC Payout32.30% Avg Volume3.17M Price120.44
Recom2.30 SMA201.11% SMA503.14% SMA2003.60% Volume503,750 Change1.18%
18-Jul-14Reiterated Deutsche Bank Buy $144 → $149
23-Apr-14Reiterated Oppenheimer Perform $121 → $122
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
09-Feb-12Downgrade Oppenheimer Outperform → Perform
09-Sep-11Downgrade Standpoint Research Buy → Hold
10-May-11Reiterated MP Advisors Outperform $63 → $65
22-Jul-14 06:13AM  [$$] 9 Health Care Stocks From Index-Crushing Fund at Barrons.com
21-Jul-14 03:11PM  Astellas Up on Pipeline Update, Oncology in Focus (revised) Zacks
01:15PM  Amgen's AMG 416 Succeeds in Phase III, Shares Up Zacks
18-Jul-14 03:40PM  Biotech Enters Reporting Season With Large Caps Central To Sector Performance Benzinga
07:26AM  Amgen: Grappling With The Reality Of Patent Expiries at Seeking Alpha
17-Jul-14 05:52PM  Amgen parathyroid drug found effective in kidney patient trial Reuters
05:32PM  [$$] Amgen Hormone Drug Proves Positive in Study at The Wall Street Journal
04:29PM  Amgen thyroid drug succeeds in late stage kidney patient trial Reuters
04:01PM  Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis PR Newswire
16-Jul-14 02:50PM  Astellas Up on Pipeline Update, Oncology in Focus Zacks
10:15AM  4 Top Biotechs Expected to Beat Earnings Expectations at 24/7 Wall St.
15-Jul-14 02:24PM  Q2 2014 Update: My Whistler Income And Growth Portfolio at Seeking Alpha
11:21AM  Amgen (AMGN) Roof Leaking Today at TheStreet
10:33AM  Facebook, Twitter slip following cautious valuation comments from Fed at theflyonthewall.com
14-Jul-14 01:14PM  3 Stocks Reiterated As A Buy: AXP, BIDU, AMGN at TheStreet
10-Jul-14 08:20AM  The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks
09-Jul-14 11:52AM  Celgene Drug Otezla Fails Trial, But Street Sanguine at Investor's Business Daily
08-Jul-14 02:42PM  Alexion Pharma Looks To Life Beyond Its Blockbuster at Investor's Business Daily
10:03AM  Gilead Sciences: How Big a Beat? at Barrons.com
08:54AM  Story Stocks from Briefing.com Briefing.com
08:39AM  Story Stocks from Briefing.com Briefing.com
07-Jul-14 10:28AM  Story Stocks from Briefing.com Briefing.com
09:48AM  Story Stocks from Briefing.com Briefing.com
09:17AM  Story Stocks from Briefing.com Briefing.com
08:46AM  Story Stocks from Briefing.com Briefing.com
03-Jul-14 03:30PM  BIND Therapeutics Ends Oncology Deal with Amgen Zacks
12:38PM  Gilead Sciences: Time for an Earnings Beat? at Barrons.com
12:26PM  Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector Benzinga
12:17PM  Story Stocks from Briefing.com Briefing.com
12:04PM  Ligand Pharmaceuticals: Appendix at Seeking Alpha
11:31AM  Bind Therapeutics Down After Losing Amgen Partnership at Investor's Business Daily
10:41AM  Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge 7.5% Benzinga
10:35AM  Interested In Healthcare Stocks? Look At This ETF at Investopedia
10:07AM  Stocks to Watch: Lululemon, Bind Therapeutics, Regado Biosciences at The Wall Street Journal
09:18AM  Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today at TheStreet
07:52AM  Early movers: APP, MS, LULU, BIND, ABBV & more at CNBC
07:15AM  Story Stocks from Briefing.com Briefing.com
02-Jul-14 05:55PM  Bind Therapeutics ends cancer drug partnership with Amgen Reuters
05:10PM  Why BIND Therapeutics (BIND) Stock Is Falling In After-Hours Trading Today at TheStreet
05:02PM  3 Dividend Stocks for Summer: Amgen, Healthcare Services Group, and Quality Systems at Motley Fool
04:55PM  Amgen Gets Breakthrough Therapy Status for Leukemia Drug Zacks
05:00AM  'Fast Money' Recap: Let Your Winning Trades Keep Running at TheStreet
01-Jul-14 09:23AM  [$$] Amgen's Leukemia Drug Gets Breakthrough Designation at The Wall Street Journal
08:09AM  Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTEĀ® Antibody Blinatumomab In Acute Lymphoblastic Leukemia PR Newswire
30-Jun-14 03:16PM  Amgen Inc. Bonds: A Rare Combination Of Low Risk And High Value at Seeking Alpha
28-Jun-14 12:01AM  [$$] The World's Most Respected Companies at Barrons.com
26-Jun-14 09:02AM  Will Amgens Acquisition of Onyx Pay off Soon? at Motley Fool
09:02AM  Will Amgens Acquisition of Onyx Pay off Soon?
23-Jun-14 08:01PM  Biotech R&D spending outpaces revenue growth-report Reuters
08:01PM  Biotech R&D spending outpaces revenue growth-report
12:55PM  Supreme Court Erects Obstacle to Class Actions for Securities Fraud
12:55PM  Supreme Court Adds New Hurdle in Investors Class-Action Suits
12:55PM  New Hurdle in Investors Class Actions at New York Times
12:55PM  New Hurdle In Investors Class Actions
12:55PM  New Hurdle in Investors Class Actions
11:52AM  Tired of Paltry Junk-Bond Yields? Try These Alternatives at The Wall Street Journal
11:52AM  Tired of Paltry Junk-Bond Yields? Try These Alternatives
19-Jun-14 03:10PM  [$$] Cancer Doctors Ring Up Big Bills for Tarnished Drug at The Wall Street Journal
02:50PM  [$$] Cancer Doctors Ring Up Big Bills for Tarnished Drug at The Wall Street Journal
16-Jun-14 05:32PM  3 Undervalued Amgen Growth Opportunities to Watch at Motley Fool
05:32PM  3 Undervalued Amgen Growth Opportunities to Watch
04:03PM  Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer PR Newswire
04:03PM  Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
15-Jun-14 01:10PM  Is Gene Therapy Medicine's Next Big Thing? at Motley Fool
13-Jun-14 03:34PM  Is Amgen's Dividend Safe? at Motley Fool
03:34PM  Is Amgen's Dividend Safe?
08:03AM  What Will Happen When Biotech Drugs Go Generic? at Forbes
08:03AM  What Will Happen When Biotech Drugs Go Generic?
07:42AM  The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and AmgenThe Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen Zacks
07:42AM  The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and AmgenThe Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
12-Jun-14 06:19PM  OFFICIAL - UPDATE 3-U.S. investigating Icahn, Mickelson in insider trading probe-source Reuters
06:19PM  OFFICIAL - UPDATE 3-U.S. investigating Icahn, Mickelson in insider trading probe-source
04:10PM  Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement Zacks
04:10PM  Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement
02:12PM  Sharp Scrutiny From European Medicines Agency Of Amgen And Servier Heart Drug at Forbes
02:12PM  Sharp Scrutiny From European Medicines Agency Of Amgen And Servier Heart Drug
01:18PM  US tech and pharma park cash offshore at Financial Times
12:57PM  InterMune Up On Bullish View Of U.S. Esbriet Launch at Investor's Business Daily
12:57PM  InterMune Up On Bullish View Of U.S. Esbriet Launch
05:10AM  Is AbbVie's Dividend Safe? at Motley Fool
11-Jun-14 08:19PM  Amgen (AMGN) Management Presents at Goldman Sachs 35th Annual Global Healthcare Conference (Transcript) Seeking Alpha
05:19PM  Amgen says Phase 2 study of brodalumab met primary endpoint theflyonthewall.com
05:19PM  Amgen says Phase 2 study of brodalumab met primary endpoint
05:00PM  Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine PR Newswire
05:00PM  Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study Reuters
10:58AM  BIND Therapeutics Set To Revolutionize Drug Treatment As Clinical Data Continues To Impress at Seeking Alpha
10-Jun-14 01:04PM  3M's Loss is Amgen's Gain at Barrons.com
09:20AM  UPDATE: Morgan Stanley Reiterates On Amgen On New CFO Benzinga
06:05AM  [$$] MacroGenics Looks Immune to Downside at Barrons.com
09-Jun-14 05:41PM  [$$] 3M Finance Chief Departs for Amgen at The Wall Street Journal
04:34PM  AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
04:22PM  Amgen names former 3M CFO Meline as finance chief Reuters
04:15PM  Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer PR Newswire
07-Jun-14 11:06AM  3 Spectacular Ways Samsung Could Disrupt the Health Care Industry at Motley Fool
06-Jun-14 04:15PM  Amgen To Present At The Goldman Sachs Global Healthcare Conference PR Newswire
05-Jun-14 06:31PM  2 Reasons to Watch Amgen, Inc. at Motley Fool
07:36AM  The Zacks Analyst Blog Highlights: Pharmacyclics, AbbVie, Gilead, Amgen and Celgene. Zacks
04-Jun-14 05:04PM  Whither Amgen? A Split Is Suggested for the Biotech at The Wall Street Journal
04:19PM  Whither Amgen? A Split is Suggested for the Biotech at The Wall Street Journal
10:31AM  Time to Break Up Amgen? at Barrons.com
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM
Balachandran MadhavanEVP, OperationsSep 04Option Exercise58.4318,0001,051,74059,133Sep 05 07:33 PM
Balachandran MadhavanEVP, OperationsSep 04Sale112.7618,0002,029,76834,851Sep 05 07:33 PM
BALTIMORE DAVIDDirectorAug 28Sale109.664,582502,46227,789Aug 30 05:36 PM